Pharmaceutical News and Articles
Clinical Trial Results
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
--Poster presentations on studies in cutaneous T-cell,
peripheral T-cell and B-cell lymphoma--
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 24, 2009 - Gloucester
Pharmaceuticals today announced multiple presentations from
clinical and preclinical...
BETHESDA, Md.--(BUSINESS WIRE)--Nov 25, 2009 - Sucampo Pharma
Europe, Ltd., and Sucampo Pharma Americas, Inc., subsidiaries of
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), today presented
additional clinical data for lubiprostone (Amitiza®)
at...
Stockholm, Sweden - November 25, 2009 - Biovitrum AB (STO: BVT)
today announced that the first of two clinical phase II studies,
designed to together show proof of concept of Kiobrina(TM) (rhBSSL)
in preterm infants, has been completed. The results...
NOVATO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Raptor
Pharmaceutical Corp. ("Raptor" or the "Company") (NASDAQ:RPTP) today announced the presentation
of clinical trial data on NGX426, the Company's orally
administered, non-opioid, AMPA/kainate...
New data supports safety of Caldolor over 5 days
of treatment
NASHVILLE, Tenn., Nov. 23 /PRNewswire-FirstCall/ -- Cumberland
Pharmaceuticals Inc. (NASDAQ:CPIX) today announced positive new
top-line results from a study evaluating the safety...
Primary efficacy endpoint has been met for patients with
advanced-stage or recurrent endometrial cancer
QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ -- AEterna Zentaris
Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global
biopharmaceutical company...
Preclinical Data on A2A and Beta-2 Adrenergic Receptor
Agonist Programs in B-Cell Malignancies To Be Presented
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 24, 2009 - CombinatoRx,
Incorporated (NASDAQ: CRXX) today announced that two abstracts
highlighting...
ADX48621 shows efficacy on both chorea and dystonia in PD-LID
model
Geneva, Switzerland, 24 November 2009 - Addex Pharmaceuticals
(SWX:ADXN), the allosteric modulation company, announced today that
in a non-human primate model of Parkinson's disease...
SAN DIEGO--(BUSINESS WIRE)--Nov 23, 2009 - Nereus
Pharmaceuticals, Inc., a pioneer in drug discovery from marine
microbial sources, today announced positive interim results from a
randomized Phase 2 clinical trial evaluating the vascular
disrupting...
Cash Flow Positive, Growing Business Provides NexMed with
Pre-clinical Capabilities, Added Licensing Expertise and Critical
Mass;
Transaction May Enable Continued NASDAQ
Listing
Conference Call to Be Held at 9:00 am...
? THE DRUG CANDIDATE GFT505 STATISTICALLY MEETS ALL THE
PRIMARY END POINTS OF THE STUDY GFT505-2083 IN PREDIABETIC
PATIENTS
? THE STUDY CONFIRMS THE EXCELLENT EFFICACY TO SAFETY RATIO OF
GFT505 IN PATIENTS SUFFERING FROM ATHEROGENIC...
HASBROUCK HEIGHTS, NJ (November 23, 2009) Nymox Pharmaceutical
Corporation (NASDAQ: NYMX) announced today the release of positive
new clinical trial data from responder analysis of the
Company’s pooled multicenter U.S. Phase 2 studies of...
Parma, Italy, 19th November 2009 – The Chiesi Group, which
is based in Parma, ranks top among Italian investors in Research
and Development within the pharmaceutical sector, putting it in
eighth place in the ranking of the biggest national...
(Oslo/Tromsø, 23 November 2009) Biotec
Pharmacon has received the results from both its
phase III studies with SBG for diabetic foot ulcer and regrets to
inform that the results are not positive. The studies failed to
show superiority of SBG...
- LX1031 represents a first-in-class compound for IBS -
Inhibitor of tryptophan hydroxylase, a key enzyme in serotonin
production - First demonstration of new mechanism of action in
treatment of IBS Presentation summary will be available...
CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Dear Isis
Supporters and Shareholders,
I would like to start by thanking you for your continuing
support of Isis. We believe we are at one of the most successful
moments in our history. We...
MALVERN, Pa. and FRAZER, Pa., Nov. 23 /PRNewswire-FirstCall/ --
Ception Therapeutics, Inc., a privately held biopharmaceutical
company, and Cephalon, Inc. (NASDAQ:CEPH)
today announced results from a Phase IIb/III clinical trial for
CINQUIL(TM)...
LYSAKER, Norway, November 20 - Pronova BioPharma ASA (OSE:
PRON.OL) ("Pronova BioPharma" or the "Company") has presented at
"Aksjedagen Norge" in Tønsberg, 19 November 2009 by CEO
Morten Jurs. The presentation is attached to this release...
China’s research and development organization will become
the fourth key R&D hub for Merck Serono division worldwide
Merck plans to invest more than € 150 million
Darmstadt, November 23, 2009 – Merck KGaA announced today
plans...
Data Presented at International Melanoma Conference in Berlin
Results Follow Decision by Company to Continue Phase 3 AGENDA Trial
for Overall Survival
BERKELEY HEIGHTS, NJ – November 20, 2009 – Genta
Incorporated (OTCBB: GETA.OB)...
More...
